

FOR IMMEDIATE RELEASE

CONTACTS

DIPHARMA: +41(0)916011700

info@dipharma.ch

www.dipharma.ch



*Better Together.
Improved Solutions for Inborn Metabolic Diseases.*

ERRATA CORRIGE. The following press release issued on June 15th 2017 replaces the previous one released on February 23rd 2017

DIPHARMA ANNOUNCES THE VALIDATION OF DISANIT® (NITISINONE) MARKETING AUTHORIZATION APPLICATION IN EUROPE

A stable capsule formulation of Nitisinone for the treatment of hereditary Tyrosinemia type-1 (HT-1) is now under marketing authorization (MA) evaluation in the EU.

Chiasso, Switzerland – Dipharma S.A. announces the validation of the MA application for its product Disanit® (Nitisinone capsules 2, 5 and 10 mg) in the EU. The Swiss company also announces plans to file an Abbreviated New Drug Application (ANDA) with the US FDA.

Disanit® is the improved generic version of SOBI's Orfadin®, which is indicated for the treatment of hereditary tyrosinaemia type 1 (HT-1), a very rare inborn error of metabolism (IEM). Disanit® is a stable capsule formulation that can be stored at room temperature without the need of refrigeration currently up to 24 months.

Disanit® is the third product of Dipharma undergoing a regulatory marketing authorization procedure: Diterin® (sapropterin dihydrochloride 100 mg tabs) has already been approved in South Korea and Russia for the treatment of hyperphenylalaninemia (HPA) due to phenylketonuria (PKU) and Miglustat (miglustat 100 mg caps) was submitted in the USA through an abbreviated new drug application (ANDA) in 2016 for the treatment of Gaucher disease. Dipharma also confirms that the development of several other products for the treatment of rare metabolic diseases is on-going.

“Once approved, Disanit® will be the first capsule formulation of Nitisinone in Europe that can be stored at room temperature currently up to 24 months, simplifying distribution, decreasing cold-chain related wastage and finally improving ease of use for the patients” commented Marc-Olivier Geinoz, CEO of Dipharma S.A. “This regulatory filing is the perfect exemplification of our mission: in Dipharma we strive to improve the life of patients suffering from inborn errors of metabolism. We aim to provide more value to patients and health professionals, at an affordable cost for payers.”

Dipharma S.A. also announces that international patent applications were filed claiming a stable crystalline form of Nitisinone, capsule formulations of Nitisinone with improved long-term stability and the proprietary technology developed to improve the product stability, without modifying the pharmaceutical form the patients are familiar with.

Dipharma S.A. is currently working with its partners to make Disanit® and all the rest of its product portfolio available to patients worldwide.

About Disanit®

Disanit® (nitisinone 2, 5 and 10 mg) is the first capsule formulation of Nitisinone that can be stored at room temperature currently up to 24 months, currently under review by EU authorities for the treatment of hereditary tyrosinaemia type 1 (HT-1).

HT-1 is a rare inborn error of metabolism (IEM) in which the body is unable to completely break down the amino acid tyrosine, and so harmful substances are formed, causing serious liver problems and liver cancer. HT-1 is progressive and can be fatal if untreated. For more information on HT-1, please visit <http://www.dipharma.ch/rare-diseases/>.

Disanit® is to be used together with a diet that restricts the intake of the amino acids tyrosine and phenylalanine. These amino acids are normally found in proteins in foods and drinks.

Disanit® was developed by Dipharma S.A., Switzerland. Disanit® is a trademark owned by Dipharma S.A.

Disanit® will be entirely manufactured and packaged in the EU.

About Dipharma

Dipharma S.A. is a Swiss pharmaceutical company specialized in developing high quality, improved, medicines for rare diseases. Dipharma S.A. is part of a third generation group of family companies that have grown to a global presence.

With a portfolio of products for the treatment of Phenylketonuria, Gaucher Disease, Niemann Pick Type C, Hereditary Tyrosinemia Type 1, Urea Cycle Disorders and others, Dipharma SA works every day to provide improved solutions for people affected by inborn metabolic diseases at an affordable cost and with a global reach.

For more information, please visit www.dipharma.ch

Orfadin® is a registered trademark of Swedish Orphan Biovitrum

DISCLAIMER

This press release may contain certain forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, including scientific, business, economic and financial factors, which could cause actual results to differ materially from those anticipated in the forward-looking statements. The company assumes no responsibility to update forward-looking statements or adapt them to future events or developments.

Dipharma S.A. operates respectfully of any third party IP rights and/or regulatory exclusivities that may exist in each specific country.

This press release may contain information on pharmaceuticals that are not currently approved or available in your country or region.